ATOMIC ENERGY COUNCIL-INSTITUTE OF NUCLEAR ENERGYRESEARCH
发明人:
KU, PEI CHIH,古佩芝,古佩芝,LEE, SHUI CHENG,李瑞成,李瑞成,CHENG, CHUN CHIA,程俊嘉,程俊嘉
申请号：
TW099136861
公开号：
TW201216991A
申请日:
2010.10.28
申请国别(地区):
TW
年份:
2012
代理人:
摘要：
Liver fibrosis leads to liver cirrhosis and even cancer progressively, which can be prevented by early detection. Liver biopsy reported by pathologists are used as gold standard to diagnose fibrosis. However, it is invasive. A reliable tissue biomarker is desirable for designing a non-invasive diagnosing tool to replace or complement invasive liver biopsy. Presently many studies report that cannabinoid 1 receptor (CB1R) is associated with liver fibrosis, hence it is possible to measure the expression of CB1R for detecting the stages of liver fibrosis.We measure the protein expression of CB1R via detecting its antagonist, AM251, by using biomedical techniques and micro-single-photon emission computed tomography/computed tomography (SPECT/CT) and also confirm the cannabinoid 1 receptor (CB1R) on the liver fibrogenic cells in vivo. CB1R is a specific target and can be applied in nuclear imaging techniques for liver fibrosis detection. We speculate that this novel technique can be used to complement liver biopsy for diagnosing and predicting liver fibrosis in the future.一種肝纖維化分子標靶偵測劑及其核醫造影法,係提供肝纖維化細胞CB1受體之單株抗體及其拮抗劑;經放射性同位素或螢光物質標幟取得標幟物;以及將上述任一種放射性同位素或螢光物質標幟物靜脈注射入人體或動物體內進行核醫造影,並利用電腦斷層掃描進行肝纖維化之活體造影。藉此,由核醫影像之呈現偵測出肝纖維化之存在位置及空間分佈,或進一步由影像之明亮度分辨出肝纖維化之等級,在臨床上可以安全、無侵襲性並準確地檢查出各類肝病患者之肝纖維化程度,並應用於肝纖維化治療前後之診斷與追蹤,俾以達到預防醫學提倡之早期診斷早期治療之理想。11-13...步驟
